What is Claimed:

1. An orally administerable medicament comprising: deferasirox or a pharmaceutically acceptable salt thereof present in an amount of from 45% to 60% by weight based on the total weight of the medicament, said medicament having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

2. An orally medicament comprising (a) deferasirox or a pharmaceutically acceptable salt thereof; and (b) at least one pharmaceutically acceptable excipient suitable for the preparation of medicament, wherein deferasirox or a pharmaceutically acceptable salt thereof is present in an amount of from 45% to 60% by weight based on the total weight of the medicament.

3. The orally administerable medicament according to claim 1 in tablet form.

4. The orally administerable medicament according to claim 1 in pellet form or multi-particulate form.

5. The orally administerable medicament according to claim 1 in tablet form that possesses a disintegration time of 5-10 minutes when measured by a standard USP disintegration test.

6. The orally administerable medicament according to claim 5 further comprising an enteric coating.

7. The orally administerable medicament according to claim 1 further comprising:

(i) at least one filler in a total amount of about to 10% to 40 % by weight based on the total weight of the tablet;

(ii) at least one disintegrant in a total amount of about 1% to 10% by weight based on the total weight of the tablet;

(iii) at least one binder in a total amount of about 1% to 5% by weight based on the total weight of the tablet;

(iv) at least one surfactant in a total amount of about 0.0% to 2% by weight based on the total weight of the tablet;

(v) at least one glidant in a total amount of about 0.1% to 1% by weight based on the total weight of the tablet;

(vi) at least one lubricant in a total amount of less than about 0.1% to 2% by weight based on the total weight of the tablet; and

(vii) a coating, wherein the coating further comprises a functional or a non-functional polymer.

8. The medicament according to claim 7 wherein the surfactant is selected from sodium laurel sulfate and a poloxamer.

9. The medicament according to claim 8 wherein said surfactant is the polaxamer Pluronic™ F68 grade.

10. The medicament according to claim 7 wherein said medicament is further seal-coated, wherein said seal-coat is Opadry™ 03K19229 1% (0-2%).

11. The medicament according to claim 7 wherein said medicament comprises an enteric coating, where said enteric coating is selected from Eudragit™ (Acryl EZE™ 93F) at 7% (5-20%).

12. The medicament according to anyone of claims 1 to 11 containing deferasirox in its free acid form in an amount of about 50 mg to 600 mg .

13. A process for manufacturing deferasirox medicament according to claim 3 in the form of tablets, granules, pellets or multi-particulates comprising the steps of:

(i) mixing deferasirox and at least one pharmaceutically acceptable excipient;

(ii) wet-granulating the mixture obtained in step (i) in a high shear granulator followed by drying and screening to produce granulates;

(iii) mixing the granulates obtained in step (ii) with at least one pharmaceutically acceptable excipient to form a mixture;

(iv) compressing the mixture obtained in step (iii) to form a tablet; and

(v) coating the tablet.

14. A process for the preparation of a coated deferasirox tablet, comprising the steps of:

(i) mixing deferasirox or a pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient;

(ii) wet-granulating the mixture obtained in step (i) in a high shear granulator;

(iii) extruding and spheronizing the wet granulates obtained in step (ii);

(iv) drying the extruded and spheronized pellets; and

(v) coating the pellets.

15. A method of treating diseases which cause an excess of metal in a human or animal body or are causes by an excess of metal in a human or animal body comprising the step of administering a medicament according to claim 1 comprising about 50 mg to about 600 mg of a deferasirox or pharmaceutically acceptable salt thereof.

16. The method according to claim 15 wherein the metal is iron.

17. An orally administerable tablet in specific dosage forms comprising:

Component	% (w/w)	mg/648mg tab	mg/324mg tab	mg/162mg tab
Deferasirox	**55.56**	360.00	180.00	90.00
Microcrystalline cellulose PH101	**15.09**	97.81	48.91	24.45
Microcrystalline cellulose	**18.00**	116.64	58.32	29.16

PH102				
Poly Vinyl Pyrrolidone K-30	**2.25**	14.58	7.29	3.65
Crospovidone	**7.00**	45.36	22.68	11.34
Pluronic F68	**0.10**	0.65	0.32	0.16
Aerosil	**0.50**	3.24	1.62	0.81
Magnesium Stearate	**1.50**	9.72	4.86	2.43
Total	**100.00**	**648.00**	**324.00**	**162.00**
Coating				
Opadry Blue	**3.00**	19.44	9.72	4.86
Final tablet weight	**103.00**	**667.44**	**333.72**	**166.86**

.

18. An orally administrable pellet, as specific pediatric dosage forms, comprising:

Component	**% (w/w)**	**mg/720mg tab**	**mg/360mg tab**	**mg/180mg tab**
Deferasirox	**55.56**	400.00	200.00	100.00
Microcrystalline cellulose PH101™	**15.09**	108.68	54.34	27.17
Microcrystalline cellulose PH102™	**18.00**	129.60	64.80	32.40
Poly Vinyl Pyrrolidone K-30™	**2.25**	16.20	8.10	4.05
Crospovidone	**7.00**	50.40	25.20	12.60
Pluronic™ F68	**0.10**	0.72	0.36	0.18
Aerosil™	**0.50**	3.60	1.80	0.90
Magnesium Stearate	**1.50**	10.80	5.40	2.70
Total	**100.00**	**720.00**	**360.00**	**180.00**

19. An orally administerable medicament comprising a plurality of deferasirox pellets or multi-particulates, wherein each said pellets or multi-particulates comprises deferasirox, or a pharmaceutically acceptable salt thereof, present in an amount of from 45% to 60% by weight based on the total weight of the medicament, said medicament having reduced release under gastric conditions and a fast release at near neutral pH or at neutral pH.

20. The orally administerable medicament according to claim 19, comprising about 50 mg to about 600 mg of deferasirox, based upon the weight of free deferasirox.

21. The orally administerable medicament according to claim 20, wherein said plurality of pellets or multi-particulates are included in a capsule.

22. The orally administerable medicament according to claim 1, wherein the amount of deferasirox loading is increased using wet granulation or extrusion spheronization, as compared to a disperable deferasirox tablet formulation.

23. The orally administerable medicament according to claims 1 or 9, wherein the bioavailability of deferasirox is increased using wet granulation or extrusion spheronization, as compared to a disperable deferasirox tablet formulation.

24. The orally administerable medicament according to claim 23, wherein a decreased deferasirox dosage achieves a similar therapeutic efficacy as compared to a higher dosage disperable deferasirox tablet formulation.

What is Claimed:

1. An orally administerable medicament comprising: deferasirox or a pharmaceutically acceptable salt thereof present in an amount of from 45% to 60% by weight based on the total weight of the medicament, said medicament having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

2. An orally medicament comprising (a) deferasirox or a pharmaceutically acceptable salt thereof; and (b) at least one pharmaceutically acceptable excipient suitable for the preparation of medicament, wherein deferasirox or a pharmaceutically acceptable salt thereof is present in an amount of from 45% to 60% by weight based on the total weight of the medicament.

3. The orally administerable medicament according to claim 1 in tablet form.

4. The orally administerable medicament according to claim 1 in pellet form or multi-particulate form.

5. The orally administerable medicament according to claim 1 in tablet form that possesses a disintegration time of 5-10 minutes when measured by a standard USP disintegration test.

6. The orally administerable medicament according to claim 5 further comprising an enteric coating.

7. The orally administerable medicament according to claim 1 further comprising:

(i) at least one filler in a total amount of about to 10% to 40 % by weight based on the total weight of the tablet;

(ii) at least one disintegrant in a total amount of about 1% to 10% by weight based on the total weight of the tablet;

(iii) at least one binder in a total amount of about 1% to 5% by weight based on the total weight of the tablet;

(iv) at least one surfactant in a total amount of about 0.0% to 2% by weight based on the total weight of the tablet;

(v) at least one glidant in a total amount of about 0.1% to 1% by weight based on the total weight of the tablet;

(vi) at least one lubricant in a total amount of less than about 0.1% to 2% by weight based on the total weight of the tablet; and

(vii) a coating, wherein the coating further comprises a functional or a non-functional polymer.

8. The medicament according to claim 7 wherein the surfactant is selected from sodium laurel sulfate and a poloxamer.

9. The medicament according to claim 8 wherein said surfactant is the polaxamer Pluronic™ F68 grade.

10. The medicament according to claim 7 wherein said medicament is further seal-coated, wherein said seal-coat is Opadry™ 03K19229 1% (0-2%).

11. The medicament according to claim 7 wherein said medicament comprises an enteric coating, where said enteric coating is selected from Eudragit™ (Acryl EZE™ 93F) at 7% (5-20%).

12. The medicament according to anyone of claims 1 to 11 containing deferasirox in its free acid form in an amount of about 50 mg to 600 mg .

13. A process for manufacturing deferasirox medicament according to claim 3 in the form of tablets, granules, pellets or multi-particulates comprising the steps of:

(i) mixing deferasirox and at least one pharmaceutically acceptable excipient;

(ii) wet-granulating the mixture obtained in step (i) in a high shear granulator followed by drying and screening to produce granulates;

(iii) mixing the granulates obtained in step (ii) with at least one pharmaceutically acceptable excipient to form a mixture;

(iv) compressing the mixture obtained in step (iii) to form a tablet; and

(v) coating the tablet.

14. A process for the preparation of a coated deferasirox tablet, comprising the steps of:

(i) mixing deferasirox or a pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient;

(ii) wet-granulating the mixture obtained in step (i) in a high shear granulator;

(iii) extruding and spheronizing the wet granulates obtained in step (ii);

(iv) drying the extruded and spheronized pellets; and

(v) coating the pellets.

15. The medicament according to claim 1 comprising about 50mg to about 600mg of a deferasirox or pharmaceutically acceptable salt thereof for treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body.

16. The medicament according to claim 15 wherein the metal is iron.

17. An orally administerable tablet in specific dosage forms comprising:

Component	% (w/w)	mg/648mg tab	mg/324mg tab	mg/162mg tab
Deferasirox	**55.56**	360.00	180.00	90.00

Microcrystalline cellulose PH101	**15.09**	97.81	48.91	24.45
Microcrystalline cellulose PH102	**18.00**	116.64	58.32	29.16
Poly Vinyl Pyrrolidone K-30	**2.25**	14.58	7.29	3.65
Crospovidone	**7.00**	45.36	22.68	11.34
Pluronic F68	**0.10**	0.65	0.32	0.16
Aerosil	**0.50**	3.24	1.62	0.81
Magnesium Stearate	**1.50**	9.72	4.86	2.43
Total	**100.00**	**648.00**	**324.00**	**162.00**
Coating				
Opadry Blue	**3.00**	19.44	9.72	4.86
Final tablet weight	**103.00**	**667.44**	**333.72**	**166.86**

.

18. An orally administrable pellet, as specific pediatric dosage forms, comprising:

Component	**% (w/w)**	**mg/720mg tab**	**mg/360mg tab**	**mg/180mg tab**
Deferasirox	**55.56**	400.00	200.00	100.00
Microcrystalline cellulose PH101™	**15.09**	108.68	54.34	27.17
Microcrystalline cellulose PH102™	**18.00**	129.60	64.80	32.40
Poly Vinyl Pyrrolidone K-30™	**2.25**	16.20	8.10	4.05
Crospovidone	**7.00**	50.40	25.20	12.60
Pluronic™ F68	**0.10**	0.72	0.36	0.18
Aerosil™	**0.50**	3.60	1.80	0.90
Magnesium Stearate	**1.50**	10.80	5.40	2.70
Total	**100.00**	**720.00**	**360.00**	**180.00**

19. An orally administerable medicament comprising a plurality of deferasirox pellets or multi-particulates, wherein each said pellets or multi-particulates comprises deferasirox, or a pharmaceutically acceptable salt thereof, present in an amount of from 45% to 60% by weight based on the total weight of the medicament, said medicament having reduced release under gastric conditions and a fast release at near neutral pH or at neutral pH.

20. The orally administerable medicament according to claim 19, comprising about 50 mg to about 600 mg of deferasirox, based upon the weight of free deferasirox.

21. The orally administerable medicament according to claim 20, wherein said plurality of pellets or multi-particulates are included in a capsule.

22. The orally administerable medicament according to claim 1, wherein the amount of deferasirox loading is increased using wet granulation or extrusion spheronization, as compared to a disperable deferasirox tablet formulation.

23. The orally administerable medicament according to claims 1 or 9, wherein the bioavailability of deferasirox is increased using wet granulation or extrusion spheronization, as compared to a disperable deferasirox tablet formulation.

24. The orally administerable medicament according to claim 23, wherein a decreased deferasirox dosage achieves a similar therapeutic efficacy as compared to a higher dosage disperable deferasirox tablet formulation.